

The full name of Trio is *Triple functional domain* because mammalian Trio contains three enzymatic domains: An N-terminal GEF (GEF1) domain, a C-terminal GEF (GEF2) domain and a protein serine/threonine kinase (PSK) domain locating at the most C-terminal. The two GEF domains activate the Rho family GTPases via accelerating GTP/GDP exchange, while the function of the PSK domain is still unknown and less studied, but structurally, this domain has a high sequence similarity to calcium/calmodulin dependent PSKs, such as myosin light chain kinase (MLCK). Trio orthologs in invertebrates, such as *C. elegans UNC-73* and *Drosophila trio* lack the kinase domain^{10, 11}, suggesting that new functions of the multi-domain protein may emerge in vertebrates, although human Trio does not show any kinase activity to a number of artificial substrates by *in vitro* assays⁹. In developing rodent brain, multiple isoforms of Trio are expressed^{12, 13}. The expression of the kinase domain-containing full-length Trio is extremely low in the nervous system compared with other shorter isoforms. Both of the two shorter isoforms, Trio9L and Trio9S (also known as TrioD and TrioA, respectively) contain both GEF1 domain and GEF2 domain, and express as the most abundant isoforms in the brain, thus the most abundant isoforms show the highest similarities to their orthologs in worm and fly. An even shorter isoform Trio8 (also known as TrioC) that contains only GEF1 domain but no GEF2 domain is cerebellum-specific, highlighting its role in cerebellar development.

This review briefly discusses the biochemical and cell biological properties of Trio GEFs before focusing on the genetic evidence of Trio's role in neuronal development and synaptic transmission. We will further discuss the mutations identified in individuals with neurodevelopmental disorders.

Trio is a GEF regulating multiple Rho GTPases

The biochemistry and the downstream cell biological functions of the two GEF domains of Trio have been extensively studied. The earliest work has proved *in vitro* that both the two GEF domains are functional. GEF1 domain is responsible for the activation of Rac1, while GEF2 domain is specific for RhoA activation⁹. The activity and specificity were further confirmed by evidence obtained from cell culture experiments¹⁴. Overexpression of GEF1 domain triggers JNK activation by MAPK pathway and produces membrane ruffles, both of which are the result of Rac1 activation. On the other hand, overexpression of GEF2 domain leads to the formation of stress fibers, which is the marker of RhoA activation. This observation of cytoskeleton rearrangements induced by Trio GEF domains is consistent with the later result that GEF1 domain enhances cell migration¹⁵. Another Rho GTPase RhoG might also be a direct target of Trio GEF1 domain, because GEF1 domain preferentially binds RhoG(T17N)

but not Rac1(T17N) in a yeast two-hybrid system, and expressing dominant-negative RhoG completely abolishes Trio GEF1 function while dominant-negative Rac1 or Cdc42 only partially blocks Trio GEF1 signaling¹⁶. This Trio GEF1/RhoG pathway is also involved in NGF induced PC12 cell neurite outgrowth process¹⁷, as Trio protein accumulates in the soluble fraction of PC12 cells after NGF stimulation. Moreover, the function of Trio in neurite outgrowth of PC12 cells is completely blocked by dominant-negative RhoG, while only partial or mildly inhibition is observed by dominant-negative Rac1 or Cdc42. These results from the early *in vitro* studies suggest that Trio might indirectly activate Rho GTPases Rac1 or Cdc42 through the direct activation of RhoG.

Trio in neuronal development of invertebrate

Trio's function and the underlying mechanism in neuronal development have been extensively studied in invertebrates. In *C. elegans*, UNC-73 is the ortholog of both Trio and Kalirin (a Trio paralog). The expression of UNC-73 in the nervous system is highest, and mutations in UNC-73 show abnormalities in axon extension, neuronal migration, and growth cone turning¹⁰. SLT-1 and UNC-6 are the *C. elegans* orthologs of mammalian Slit-1 and Netrin-1, and SAX-3 and UNC-40 are the orthologs of mammalian Robo and DCC. UNC-73 was found to increase the surface expression of SAX-3 and UNC-40 to enhance SLT-1 and UNC-6 mediated pathways, respectively^{18, 19}. In addition, UNC-73 is negatively regulated by CRML-1, the *C. elegans* ortholog of mammalian CARMIL. CAML-1 inhibits the GEF activity of UNC-73, thus regulating SAX-3 level in the growth cone²⁰. UNC-73 is also involved in mediating UNC-6 induced inhibition of filopodia protrusion in axon repulsion of VD neurons²¹. Recently, UNC-73 was shown to determine the direction specificity of neuritogenesis of bipolar PLM neurons, in which UNC-73 activates both CED-10/Rac1 and MIG-2/RhoG to regulate anterior neurite extension, while the posterior extension is regulated by TIAM-1²².

Drosophila Trio was identified by the genetic screen for photoreceptor axon guidance mutants, which showed similar axon projection defects to *Pak* and *dock* mutants¹¹. A point mutation in the first GEF domain of *Drosophila* Trio enhances the axon pathfinding defect of *abl* mutation by a dosage-sensitive way²³, revealing Trio functions in *Drosophila* axon pathfinding by activation of rac and regulation of cytoskeleton dynamics. Trio genetic interacts with rac in a dosage-sensitive manner, and *Trio* null mutation phenocopies *rac* mutants²⁴. Receptor protein tyrosine phosphatases(RPTPs) play roles in mediating guidance cue-induced growth cone motility, and RPTP mutations show axon guidance defects. Similarly, the phenotypes of a mutant of a RPTP member *Dlar* are potentiated by *Trio* null mutation²⁴. *Dlar* is the fly ortholog of human LAR, which is the first identified Trio interacting protein⁹, as mentioned

above. Moreover, Trio is enriched in the mushroom body of *Drosophila*, and controls the development of mushroom body²⁵. Besides axon extension and guidance, *Drosophila* Trio also functions in dendritic arborization in PNS sensory neurons. *Trio* mutants or knockdown display reduced dendritic branching and increased branch length, while overexpression of Trio displays the opposite phenotypes²⁶.²⁷. Of noted, the GEF2 domain is also involved in the regulation of dendritic arborizations, in a manner that this domain interacts with Rho1 to restrict dendritic extension and higher-order branching²⁷. Thus, Trio may function in both axon and dendrite development through both GEF domains.

Trio in neuronal development of vertebrate

In vitro functions of Trio in axon outgrowth and guidance have also been extensively studied in cultured mammalian cells. In PC12 cells, Trio and Kidins220 co-localize at the tips of neurites, activating Rac1 and mediating NGF induced neurite outgrowth²⁸. Trio is implicated to be a microtubules plus-end-tracking protein (+TIP), and interact with EB1 in the mouse hippocampal neurons. EB1 enhances Trio's activity to Rac1 by recruiting to the microtubules to form a Nav1-Trio complex, which is required for neurite outgrowth²⁹. Trio's activity is also negatively regulated in the hippocampal neurons. The binding of proNGF with p75 neurotrophin receptor - SorCS2 complex will dissociate the binding of Trio with this complex, resulting in decreased Rac1 activity, which further leads to growth cone collapse³⁰.

Results from Trio global knock out mouse provided the first genetic evidence of Trio in neural development³¹. Trio-knockout embryos die between E15.5 and birth with abnormal brain development including disorganized dentate gyrus cells in the hippocampal formation and mitral cell layer in the olfactory bulb. In addition, Trio also controls the neuronal clusters in the hindbrain, as Trio-knockout mice also show abnormal cellular organization in both the inferior olivary nuclei (ION) and facial motor nuclei (fMN) where Cadherin-11 is expressed and found in a complex with Trio³². To explore the *in vivo* functions of Trio during cerebellar development, Trio conditional knockout mice were generated³³. The authors first crossed Trio flox mice with *Nestin-Cre* to drive Trio deletion in the nervous system. Neural-specific knockout mice live longer than the global knockout mice, allowing the authors to study the behavior of cerebellar granule neurons (CGNs) postnatally. Most of the knockout pups die within 24 hours after birth and the survived mice develop a smaller brain and ataxia phenotype. Most importantly, in Trio deficient cerebella, there is an absence of granule cells in the inner granule cell layer as the migration of the granule cells from the outer granule cell layer to the inner granule cell layer is affected. Trio's role in cerebellar development seems to be neuron-specific, since ablation of Trio by hGFAP-Cre shows normal

development and normal Bergmann glia morphology. Mice with *Emx1-Cre* mediated Trio deletion in the hippocampus and cortex live to adulthood, but also with a smaller brain, an abnormal dentate gyrus phenotype and decreased hippocampal-dependent spatial learning ability³⁴. Trio deletion by *Neurod6-Cre* in the excitatory neurons of cortex and hippocampus also results in a smaller brain size, as well as some behavioral defects³⁵. Consistent with what is observed in fly, Trio-deficient pyramidal neurons display a reduced dendritic arborization. Interestingly, these phenotypes are observed even in mice with *Trio* haploinsufficiency, suggesting the concentration of Trio protein in normal cell physiology is important.

At the cellular level, cultured Trio-deficient cortical neurons or CGNs display a shorter neurite length and more neurite branches^{33, 36}, due to aberrant cytoskeletal regulation by Rho GTPases. Strikingly, the activities of all Rac1, Cdc42, and RhoA are significantly decreased in Trio-knockout cerebellar tissue. In addition, The defect of neurite outgrowth in Trio-deficient CGNs is rescued by Cytochalasin D³⁷, an F-actin depolymerization reagent, supporting that the actin dynamics are inhibited after Trio knockout. As predicted, Trio deletion leads to abnormal growth cone structures with significantly reduced area and filopodia number, further supporting the impaired actin rearrangement in the mutant growth cone.

The function and the underlying mechanism of Trio in axon guidance were also studied in Trio knockout mice³⁶. It is found that Rac1 activation elicited by Netrin-1 is lost in Trio deficient cortex, and Trio is found to be indirectly interacted with DCC, leading to the conclusion that Trio mediates Netrin-1 induced Rac1 activation in axon outgrowth and guidance. In Trio deficient spinal cord, commissural axon projections are defective with defasciculation in the floor plate, and dorsal spinal cord explant reduces neurite extension elicited by Netrin-1, consistent with observations from cortical cultures³⁶, and CGN cultures³³. However, although Rac1 activity is dramatically decreased after the ablation of Trio, Rac1 is still activated further by Netrin-1 stimulation in the cerebellum³⁷, suggesting in the cerebellum, Trio is not exclusively required for Rac1 activation upon Netrin-1 stimulation. In fact, other known GEFs, such as DOCK180³⁸ and Tiam1³⁹ play compensatory roles in mediating Netrin-1 induced Rac1 activation. This inconsistency with cortex perhaps stems from the different intrinsic properties between these two tissues. In addition, cultured Trio-deficient CGNs also lost the neurite outgrowth responsiveness elicited Semaphrin-6A, but not by NGF or glutamate³³, suggesting Trio may underlie some other signal transduction pathway downstream of guidance cues and growth factors beyond Netrin-1. A recent study demonstrated that Trio is also involved in Slit2 induced RhoA activation during the development of the ventral

telencephalon and thalamocortical axons⁴⁰. Importantly, this process is mediated by the GEF2 domain. Thus, Trio appears to use different GEF domain to transduce various extracellular signaling to control different developmental processes. Although more factors upstream of Trio still remain to be identified, these results imply that Trio acts as an integrator transducing signaling from multiple extracellular guidance cues and growth factors to intracellular cytoskeletal dynamics during axon guidance.

Upstream molecular mechanism studies suggest Trio is regulated by tyrosine phosphorylation at Y2622 by the Src family kinase Fyn upon Netrin-1 stimulation, and this phosphorylation is required for mediating Netrin-1/DCC induced Rac1 activation⁴¹. Phospho-null mutation Y2622F keeps the GEF activity toward Rac1, but abolishes Netrin-1 induced Rac1 activation and axon elongation. The authors also found that the deletion of Trio leads to decreased cell surface level of DCC in the growth cone and this abnormality could not be rescued by re-expressing the Y2622F mutant, suggesting tyrosine phosphorylation at Y2622 is required for mediating Netrin-1/DCC signaling. Interestingly, only full-length Trio contains Y2622 site and its expression in neurons is much lower than other shorter isoforms^{12,13}, thus, the function of other main isoforms of Trio in mediating Netrin-1/DCC signaling remains to be studied. Trio is also regulated by a molecular chaperone Hsc70 (heat shock cognate protein 70). Hsc70 enhances Trio GEF activity toward Rac1 and increases axon length in cortical neurons. Hsc70 interacts with Trio through the N-terminal domain and GEF1 domain, and regulates Trio localization in the growth cone periphery upon Netrin-1 stimulation⁴².

To study the function of each GEF domain of Trio and their downstream signaling in neurite outgrowth, mice with specific knockout of each GEF domain were attempted to be generated. Although gene targeting strategies that would not produce frame-shift were applied, mutant Trio with deletion of fragments in each of the two GEF domain were actually not expressed³⁷, preventing the authors to study the functions of each GEF using this genetic approach. Mice with GEF1 domain knockout are distinguishable from the previous Trio knockout mice. However, multiple splicing isoforms are expressed in the cerebellum^{12,13}, especially the Trio8 isoform that contains only GEF1 domain but with no GEF2 domain, the GEF2 domain knockout strategy actually results in mice expressing only Trio8 in the cerebellum, thus, the function of GEF2 domain or the longer isoforms (Trio-FL, Trio9L and Trio9S) has been studied using this model. Studies using these GEF2 knockout mice demonstrated that both the neurite length and the growth cone morphology are not distinguishable from control neurons, suggesting GEF2 domain does not participate in the neurite outgrowth of CGNs. However, the Netrin-1

induced neurite elongation is abrogated, implying that the GEF1 domain and its N-terminal sequences are not solely responsible for mediating Netrin-1 signaling. In addition, to study the downstream pathway the GEF1 domain is involved in neurite outgrowth in CGNs, the authors first analyzed the phenotype of Rac1-deficient CGNs isolated from Rac1 knockout mice. Surprisingly, neurite length of Rac1-deficient CGNs is normal, but the growth cone displays a phenotype of reduced area and filopodia number. On the other hand, knockdown of Cdc42 produces a significantly reduced neurite length and constitutive-active Cdc42 restores the neurite outgrowth defect. The authors concluded that at least in CGNs, Cdc42 rather than Rac1 mediates Trio's function in neurite outgrowth.

Above studies on Trio's role in neuronal development focusing on its regulation of cytoskeletal dynamics, however, membrane trafficking is also key for neuronal development and offers the membrane materials for growth and receptors for guidance. Since Trio is associated with trans-Golgi network and immature secretory granules and regulates secretion in neuroendocrine cells⁴³, the possibility that Trio may be involved in membrane trafficking during neurite outgrowth was also explored⁴⁴. Using subcellular fractionation and immunofluorescence, a pool of Trio with Golgi localization was identified in the developing cerebellum and cultured CGNs. Trio-deficient CGNs exhibit abnormal membrane trafficking, and the membrane vesicles that destined to the growth cone display an increased turning frequency as well as a decreased running distance, without any change in velocity of movements. Further, the authors showed that activities of Rab GTPases members, both Rab8 and Rab10 are decreased in Trio-deficient CGNs, and constitutive-active Rab8 or Rab10 rescues the neurite outgrowth defect. Biochemically, Trio interacts with Rab GEF Rabin8 to regulate its phosphorylation and GEF activity. Thus, this study suggests the possibility of the interaction of two GEF families in the coordination of both cytoskeletal dynamics and membrane trafficking during neuronal development.

Trio in synaptic transmission

Besides the function of Rho GTPases elucidated in axon outgrowth and guidance, they are also implicated in the modulation of dendritic spines and synaptic function. Most importantly, Rac1 plays an essential role in the maintenance of morphology and density of dendritic spines⁴⁵⁻⁴⁷, thus Rac1 GEFs must be involved in this process. It is known that Kalirin-7 is highly enriched in the postsynaptic densities⁴⁸, and overexpression of Kalirin-7 in cortical neurons results in increased numbers of spine-like structures⁴⁹. However, Kalirin-depleted neurons show brain region-specific phenotype that knockout of Kalirin results in significantly decreased spine density in the frontal cortex but not in the hippocampus⁵⁰, suggesting Trio may play redundant

functions in the maintenance of spine morphologies. Actually, a recent study demonstrated that both Trio and Kalirin play postsynaptic roles in AMPAR up-regulation in hippocampus CA1 pyramidal neurons⁵¹. The authors observed that overexpression of either Kalirin-7 or Trio-9 in CA1 pyramidal neurons produces a significant increase in AMPAR-mEPSC amplitude, but not in NMDAR-mEPSC amplitude. This postsynaptic function of Rac1 GEFs is specific for Kalirin and Trio since another Rac1 GEF Tiam1 does not produce a similar result. Conversely, the knocking down of either Kalirin-7 or Trio-9 results in a ~60% reduction of AMPAR-mEPSC amplitude and a moderate reduction of NMDAR-mEPSC amplitude. Strikingly, knocking down both Kalirin-7 and Trio-9 results in nearly complete elimination of both AMPAR- and NMDAR-mEPSCs. This loss of synaptic strength is attributed to the loss of synapses since a ~80% reduction of dendritic spines is observed in neurons lacking of both Kalirin-7 and Trio-9. The authors further suggested that phosphorylation of both Kalirin and Trio by CaMKII mediates CaMKII induced LTP. The function of Trio on the postsynaptic regulation is complex and controversial. The effect of Trio knockdown in AMPAR- and NMDAR-mEPSC amplitude is consistent with the result in Trio-knockout mice³⁵. However, a different phenotype of dendritic spine density is observed, that a significant increase of spine density is induced after Trio knockout in both cortical neurons and hippocampal CA1 neurons³⁵. There is also evidence supporting that down-regulating of Trio reduces AMPAR endocytosis thus increase surface AMPAR, since they observed less internalized GluA1 after Trio knockdown⁵², however, not consistent with others, they observed increased AMPAR-mEPSC amplitude after Trio knockdown in the meantime. So far, what is clear is that Trio's function seems specific to AMPAR rather than NMDAR. Regardless of the differences observed by different groups, the dendritic spine induction role of Trio-Rac1 axis is negatively regulated by a phospholipid-binding protein SEC14 and spectrin domains 1 (SESTD1), in a manner that SESTD1 interferes the interaction between Trio and Rac1⁵³. Overexpression of SESTD1 in hippocampal neurons significantly reduces dendritic spines while knocking down of SESTD1 induces a significant increase in spine density in hippocampal neurons. This observation further supports the positive role of Trio in the synaptic transmission.

Trio also functions presynaptically, since the frequencies of AMPAR- and NMDAR-mEPSC are also decreased in Trio knockout mice. The decreased frequencies may be attributed to the abnormal presynaptic release of neurotransmitters since an increased paired-pulse ratio is also observed in Trio-deficient neurons³⁵. The function of Trio in regulating neurotransmitter release is supported by its presynaptic localization. In addition to dendritic spines, Trio localizes in the presynaptic terminals and interacts with presynaptic active zone proteins Piccolo

and Basson⁵⁴, thereby regulating cytoskeletal assembly at the presynaptic active zone required for synaptic vesicles fusion. In *C. elegans*, UNC-73/Rho axis affects locomotion by modulating the dense core vesicle-mediated releasing of neuropeptides or neuromodulators in motor neurons⁵⁵. Genetic evidence in *Drosophila* suggests Trio is required for synaptic growth at the neuromuscular junction (NMJ)^{56,57}. In fly motor neurons, Rac activity-induced NMJ overgrowth is dependent on an intact BMP signaling which regulates Trio expression. Heterozygotic *trio* mutant showed an over 50% reduction in Rac-induced increase in synapse number⁵⁶. As expected, a significant reduction of synaptic boutons numbers is also observed in *trio* null mutant larvae and is rescued by re-expression of Trio in motor neurons, suggesting Trio functions presynaptically for synapse growth at NMJ. In addition, Trio may also regulate NMJ growth through the activation of diaphanous. In motor neurons of *diaphanous* mutant fly, the synapse growth is impaired. Diaphanous is a rho effector and plays functions in both maintenances of the presynaptic actin cytoskeleton and modulating the behavior of dynamic pioneer microtubules⁵⁷. Thus, Trio functions presynaptically at least through the regulation of both actin and microtubules dynamics. It remains to be elucidated that whether Trio is involved in presynaptic neurotransmitter release by a similar mechanism underlying endocrine cell exocytosis^{43,58} or membrane trafficking during neurite outgrowth⁴⁴.

Trio in neural disorders

The essential roles Trio plays in neuronal development and synaptic transmission directly implicate that Trio mutations in humans may lead to several neural diseases. The identification of Trio mutants in human individuals has emerged since the whole exon sequencing (WES) was applied in clinical diagnostic settings. The first report identified two *de novo* missense mutations p.Asp1368Val and p.Thr2563Met in two patients, respectively⁵⁹. Both patients are with severe intellectual disability, regardless of that they also carry another *de novo* mutations in other known intellectual disability genes, PDHA1 and TCF4, respectively. Genomic microarray, which is routinely used to detect copy-number variations (CNVs) in the clinical evaluation of intellectual disability and developmental delay, further identified a 235-kb deletion in *TRIO* locus in an individual with developmental delay and facial dysmorphisms⁶⁰. A follow-up study using molecular inversion probes further identified three additional mutations in *TRIO* in additional individuals with mild to borderline intellectual disability⁵². These mutations include two nonsense mutations, p.Trp1376* and p.Arg217* and a frameshift truncating mutation Asp1251Valfs*11. Another truncating mutation p.Gln1489Argfs*11 resulting in *TRIO* degradation was identified in a girl, as well as her father

and uncle⁶¹. These three family members presented global developmental delay and mild learning difficulties. Interestingly, this family was previously reported to have Stoll syndrome, characterized by digital abnormalities and micrognathia⁶², suggesting Trio might also be responsible for the syndrome phenotype. Three other *de novo* missense mutations were also simultaneously reported in the children recruited to the Deciphering Developmental Disorders (DDD) study⁶¹. Among these mutations, p.Arg1428Gln and p.Pro1461Thr locate in the GEF1 domain and significantly reduce the GEF activity toward Rac1, while the p.Asn1080Ile mutation locates in the spectrin repeats and shows no altered GEF activity toward Rac1. This study implicates that the mutations in Trio GEF1 domain result in intellectual disability and microcephaly, and the mutation in the spectrin repeats may also contribute to intellectual disability. More comprehensive studies identified several other *de novo* mutations in autism spectrum disorder, schizophrenia, intellectual disability, and epileptic encephalopathy^{63, 64}. Most of these mutations are discovered in the GEF1 domain, but several missense mutations are also found in the spectrin repeats and the GEF2 domain. Interestingly, five of the six mutations in the GEF1 domain are predicted to disrupt Rac1 activation, while the mutation p.Asp1368Val is experimentally validated to increase the GEF activity toward Rac1⁶³. In fact, transfection of Trio with mutation p.Lys1431Met or p.Pro1461Thu into rat hippocampal CA1 pyramidal neurons results in reduced AMPAR-eEPSC amplitude, while transfection of Trio with the mutation p.Asp1368Val dramatically increases AMPAR-eEPSC amplitude and dendritic spine density⁶³, suggesting mutations in the GEF1 domain impact glutamatergic neurotransmission in both hypomorphic and hypermorphic manner, by decreasing and increasing the GEF activity to Rac1, respectively. On the other hand, a rare sequence variant p.Met2145Thu in the GEF2 domain significantly increases the GEF activity to RhoA⁶⁴. Although the function of this variant in neuronal development and synaptic transmission is not studied, individual bearing this mutation has bipolar disorders. In addition, besides the mutations in the GEF domains, another mutation such as p.Glu883Asp in the spectrin repeats is also found to be associated with autism, further confirms that some mutations in the spectrin repeats may also interfere with Trio's function.

Trio's function beyond the nervous system

Besides those studies on the nervous system, Trio is also implicated to function in other cellular processes. In endocrine cells, Trio is activated by Cdk5, further lead to Rac1 activation and cytoskeleton changes to mediate the subsequent hormone exocytosis and release⁵⁸. Application of GEF1 domain-specific inhibitor⁶⁵ to AtT-20 cells leads to a decrease of hormone-releasing and overexpression

of the GEF1 domain leads to an accumulation of hormone molecules⁴³. In skeletal muscle, Trio is implicated to function in myoblast fusion^{31, 66}. Trio interacts with cadherins at adherens junctions and Trio knockdown blocks M-cadherin mediated adhesion, which is required for myoblast fusion⁶⁶; On the other hand, Cadherin-11 is required for *Xenopus* cranial neural crest cells migration through binding with Trio and activation of Rac1⁶⁷. Cadherin-11/Trio/Rac1 signaling also functions in breast cancer cell migration under the control of HOXC8⁶⁸. The interaction of Trio and cadherin also takes part in the adherens junctions of vascular endothelial cells, where VE-cadherin activates Rac1 through binding with Trio to increase endothelial resistance⁶⁹. Endothelial Trio also helps form a docking site required for promoting leukocyte transendothelial migration⁷⁰. Trio's function in enhancing cell migration is also implicated in some tumor or normal cells⁷¹⁻⁷⁴. Trio/Rac1 is identified to function counteracting with MgcRacGAP during cytokinesis in dividing cells⁷⁵, and transducing mitogenic signals from GPCR to control cell growth⁷⁶. Trio/RhoG axis plays a role in the formation of circular dorsal ruffles, which is associated with cell migration, micropinocytosis and receptor internalization⁷⁷. These above numerous studies are all on Trio GEF1 domain, while concerning on Trio GEF2/RhoA, the studies were countable. Trio GEF2/RhoA signaling is involved in the activation of Shroom3, whose activity is required for the shape-changing process called apical constriction, a process accompanied by lens pit invagination during eye development⁷⁸. Another study is that Echo30 virus infection activates Trio GEF2/RhoA, further leads to neuronal cell death⁷⁹.

Concluding remarks

It has been over 20 years since the Trio protein was identified and studies on Trio have been switched from early biochemistry and cell biology to human genetics. Much progress has been made in the biochemical properties and genetic functions during development and physiology, however, many questions still remain to be answered. For example, why are there expressed multiple isoforms in developing brain and different brain regions? Does Trio in all neuronal types present the same functions and regulations? What determines Trio in discrimination of various extracellular signaling? What are the *in vivo* functions and substrates of the unexplored kinase domain? Future detailed studies are needed to understand the function of Trio in neuronal development and related disorders in various regions and different time, and to develop promising therapeutic strategies in treating these diseases.

Acknowledgements

This work was supported by grants from the National

Natural Science Foundation of China (31272311 and 31330034) to M.S.Z.

Conflict of Interest

The authors declare no conflict of interest.

References

- Govek EE, Newey SE, Van Aelst L. The role of the Rho GTPases in neuronal development. *Genes Dev.* 2005; 19(1): 1-49.
- Hall A, Lalli G. Rho and Ras GTPases in Axon Growth, Guidance, and Branching. *CSH Perspec Biol.* 2010; 2(2): a001818.
- Zamboni V, Jones R, Umbach A, et al. Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities. *Int J Mol Sci.* 2018; 19(6): 1821.
- Nadif Kasri N, Van Aelst L. Rho-linked genes and neurological disorders. *Pflügers Archiv - European Journal of Physiology.* 2008; 455(5): 787-797.
- Martinelli S, Krumbach OHF, Pantaleoni F, et al. Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes. *Am J Hum Genet.* 2018; 102(2): 309-320.
- Reijnders MRF, Ansor NM, Kousi M, et al. *RAC1* Missense Mutations in Developmental Disorders with Diverse Phenotypes. *Am J Hum Genet.* 2017; 101(3): 466-477.
- Jaffe AB, Hall A. RHO GTPASES: Biochemistry and Biology. *Annu Rev Cell Dev Biol.* 2005; 21(1): 247-269.
- Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. *Nat Rev Mol Cell Biol.* 2005; 6(2): 167-180.
- Debant A, Serra-Pages C, Seipel K, et al. The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. *Proc Natl Acad Sci USA.* 1996; 93(11): 5466-5471.
- Steven R, Kubiseski TJ, Zheng H, et al. UNC-73 activates the Rac GTPase and is required for cell and growth cone migrations in *C-elegans*. *Cell.* 1998; 92(6): 785-795.
- Newsome TP, Schmidt S, Dietzl G, et al. Trio combines with Dock to regulate Pak activity during photoreceptor axon pathfinding in *Drosophila*. *Cell.* 2000; 101(3): 283-294.
- McPherson CE, Eipper BA, Mains RE. Multiple novel isoforms of Trio are expressed in the developing rat brain. *Gene.* 2005; 347(1): 125-135.
- Portales-Casamar E, Briancon-Marjollet A, Fromont S, et al. Identification of novel neuronal isoforms of the Rho-GEF Trio. *Biol Cell.* 2006; 98(3): 183-193.
- Bellanger JM, Lazaro JB, Diriong S, et al. The two guanine nucleotide exchange factor domains of Trio link the Rac1 and the RhoA pathways in vivo. *Oncogene.* 1998; 16(2):147-152.
- Seipel K, Medley Q, Kedersha N, et al. Trio amino-terminal guanine nucleotide exchange factor domain expression promotes actin cytoskeleton reorganization, cell migration and anchorage-independent cell growth. *J Cell Sci.* 1999; 112(12): 1825-1834.
- Blangy A, Vignal E, Schmidt S, et al. TrioGEF1 controls Rac- and Cdc42-dependent cell structures through the direct activation of rhoG. *J Cell Sci.* 2000; 113(4): 729-739.
- Estrach S, Schmidt S, Diriong S, et al. The Human Rho-GEF trio and its target GTPase RhoG are involved in the NGF pathway, leading to neurite outgrowth. *Curr Biol.* 2002; 12(4): 307-312.
- Watari-Goshima N, Ogura Ki, Wolf FW, et al. *elegans* VAB-8 and UNC-73 regulate the SAX-3 receptor to direct cell and growth-cone migrations. *Nat Neurosci.* 2007; 10(2): 169-176.
- Levy-Strumpf N, Culotti JG. VAB-8, UNC-73 and MIG-2 regulate axon polarity and cell migration functions of UNC-40 in *C. elegans*. *Nat Neurosci.* 2007; 10(2): 161-168.
- Vanderzalm PJ, Pandey A, Hurwitz ME, et al. *elegans* CARMIL negatively regulates UNC-73/Trio function during neuronal development. *Development.* 2009; 136(7): 1201-1210.
- Norris AD, Sundararajan L, Morgan DE, et al. The UNC-6/Netrin receptors UNC-40/DCC and UNC-5 inhibit growth cone filopodial protrusion via UNC-73/Trio, Rac-like GTPases and UNC-33/CRMP. *Development.* 2014; 141(22): 4395-4405.
- Zheng C, Diaz-Cuadros M, Chalfie M. GEFs and Rac GTPases control directional specificity of neurite extension along the anterior-posterior axis. *Proc Natl Acad Sci USA.* 2016; 113(25): 6973-6978.
- Liebl EC, Forsthoefel DJ, Franco LS, et al. Dosage-sensitive, reciprocal genetic interactions between the Abl tyrosine kinase and the putative GEF trio reveal trio's role in axon pathfinding. *Neuron.* 2000; 26(1): 107-118.
- Bateman J, Shu H, Van Vactor D. The guanine nucleotide exchange factor trio mediates axonal development in the *Drosophila* embryo. *Neuron.* 2000; 26(1): 93-106.
- Awasaki T, Saito M, Sone M, et al. The *Drosophila* trio plays an essential role in patterning of axons by regulating their directional extension. *Neuron.* 2000; 26(1): 119-131.
- Shivalkar M, Giniger E. Control of Dendritic Morphogenesis by Trio in *Drosophila melanogaster*. *PLoS ONE.* 2012; 7(3): e33737.
- Iyer SC, Wang D, Iyer EPR, et al. The RhoGEF Trio Functions in Sculpting Class Specific Dendrite Morphogenesis in *Drosophila* Sensory Neurons. *PLoS ONE.* 2012; 7(3): e33634.
- Neubrand VE, Thomas C, Schmidt S, et al. Kidins220/ARMS regulates Rac1-dependent neurite outgrowth by direct interaction with the RhoGEF Trio. *J Cell Sci.* 2010; 123(12): 2111-2123.
- van Haren J, Boudeau J, Schmidt S, et al. Dynamic microtubules catalyze formation of navigator-TRIO complexes to regulate neurite extension. *Curr Biol.* 2014; 24(15): 1778-1785.
- Deinhardt K, Kim T, Spellman DS, et al. Neuronal Growth Cone Retraction Relies on Proneurotrophin Receptor Signaling Through Rac. *Sci Signal.* 2011; 4(202): ra82-ra82.
- O'Brien SP, Seipel K, Medley QG, et al. M. Skeletal muscle deformity and neuronal disorder in Trio exchange factor-deficient mouse embryos. *Proc Natl Acad Sci USA.* 2000; 97(22): 12074-12078.
- Backer S, Hidalgo-Sanchez M, Offner N, et al. Trio controls the mature organization of neuronal clusters in the hindbrain. *J Neurosci.* 2007; 27(39): 10323-10332.
- Peng YJ, He WQ, Tang J, et al. Trio is a key guanine nucleotide exchange factor coordinating regulation of the migration and morphogenesis of granule cells in the developing cerebellum. *J Biol Chem.* 2010; 285(32): 24834-24844.
- Zong W, Liu S, Wang X, et al. Trio gene is required for mouse learning ability. *Brain Res.* 2015; 1608): 82-90.
- Katrancha SM, Shaw JE, Zhao AY, et al. Trio Haploinsufficiency Causes Neurodevelopmental Disease-Associated Deficits. *Cell Rep.* 2019; 26(10): 2805-2817 e2809.
- Briancon-Marjollet A, Ghogha A, Nawabi H, et al. Trio mediates netrin-1-induced Rac1 activation in axon outgrowth and guidance. *Mol Cell Biol.* 2008; 28(7): 2314-2323.
- Tao T, Sun J, Peng Y, et al. Distinct functions of Trio GEF domains in axon outgrowth of cerebellar granule neurons. *J Genet Genom.* 2019; 46(2): 87-96.

38. Li X, Gao X, Liu G, et al. Netrin signal transduction and the guanine nucleotide exchange factor DOCK180 in attractive signaling. *Nat Neurosci*. 2008; 11(1): 28-35.
39. Demarco RS, Struckhoff EC, Lundquist EA. The Rac GTP Exchange Factor TIAM-1 Acts with CDC-42 and the Guidance Receptor UNC-40/DCC in Neuronal Protrusion and Axon Guidance. *PLoS Genet*. 2012; 8(4): e1002665.
40. Backer S, Lokmane L, Landragin C, et al. Trio GEF mediates RhoA activation downstream of Slit2 and coordinates telencephalic wiring. *Development*. 2018; 145(19): dev153692.
41. DeGeer J, Boudeau J, Schmidt S, et al. Tyrosine Phosphorylation of the Rho Guanine Nucleotide Exchange Factor Trio Regulates Netrin-1/DCC-Mediated Cortical Axon Outgrowth. *Mol Cell Biol*. 2013; 33(4): 739-751.
42. DeGeer J, Kaplan A, Mattar P, et al. Hsc70 chaperone activity underlies Trio GEF function in axon growth and guidance induced by netrin-1. *J Cell Biol*. 2015; 210(5): 817-832.
43. Ferraro F, Ma XM, Sobota JA, et al. Kalirin/Trio Rho Guanine Nucleotide Exchange Factors Regulate a Novel Step in Secretory Granule Maturation. *Mol Biol Cell*. 2007; 18(12): 4813-4825.
44. Tao T, Sun J, Peng Y, et al. Golgi-resident TRIO regulates membrane trafficking during neurite outgrowth. *J Biol Chem*. 2019; 294(28): 10954-10968.
45. Luo L, Hensch TK, Ackerman L, et al. Differential effects of the Rac GTPase on Purkinje cell axons and dendritic trunks and spines. *Nature*. 1996; 379(6568): 837-840.
46. Nakayama AY, Harms MB, Luo L. Small GTPases Rac and Rho in the Maintenance of Dendritic Spines and Branches in Hippocampal Pyramidal Neurons. *J Neurosci*. 2000; 20(14): 5329-5338.
47. Pennucci R, Gucciardi I, de Curtis I. Rac1 and Rac3 GTPases differently influence the morphological maturation of dendritic spines in hippocampal neurons. *PLoS ONE*. 2019; 14(8): e0220496.
48. Penzes P, Johnson RC, Alam MR, et al. An Isoform of Kalirin, a Brain-specific GDP/GTP Exchange Factor, Is Enriched in the Postsynaptic Density Fraction. *J Biol Chem*. 2000; 275(9): 6395-6403.
49. Penzes P, Johnson RC, Sattler R, et al. The Neuronal Rho-GEF Kalirin-7 Interacts with PDZ Domain-Containing Proteins and Regulates Dendritic Morphogenesis. *Neuron*. 2001; 29(1): 229-242.
50. Cahill ME, Xie Z, Day M, et al. Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. *Proc Natl Acad Sci USA*. 2009; 106(31): 13058-13063.
51. Herring BE, Nicoll RA. Kalirin and Trio proteins serve critical roles in excitatory synaptic transmission and LTP. *Proc Natl Acad Sci USA*. 2016; 113(8): 2264-2269.
52. Ba W, Yan Y, Reijnders MR, et al. TRIO loss of function is associated with mild intellectual disability and affects dendritic branching and synapse function. *Hum Mol Genet*. 2016; 25(5): 892-902.
53. Lee CC, Huang CC, Hsu KS. The phospholipid-binding protein SESTD1 negatively regulates dendritic spine density by interfering with Rac1-Trio8 signaling pathway. *Sci Rep*. 2015; 5): 13250.
54. Terry-Lorenzo RT, Torres VI, Wagh D, et al. Trio, a Rho Family GEF, Interacts with the Presynaptic Active Zone Proteins Piccolo and Bassoon. *PLoS One*. 2016; 11(12): e0167535.
55. Hu S, Pawson T, Steven RM. UNC-73/Trio RhoGEF-2 Activity Modulates *Caenorhabditis elegans* Motility Through Changes in Neurotransmitter Signaling Upstream of the GSA-1/Gas Pathway. *Genetics*. 2011; 189(1): 137-151.
56. Ball RW, Warren-Paquin M, Tsurudome K, et al. Retrograde BMP Signaling Controls Synaptic Growth at the NMJ by Regulating Trio Expression in Motor Neurons. *Neuron*. 2010; 66(4): 536-549.
57. Pawson C, Eaton BA, Davis GW. Formin-Dependent Synaptic Growth: Evidence That Dlar Signals via Diaphanous to Modulate Synaptic Actin and Dynamic Pioneer Microtubules. *J Neurosci*. 2008; 28(44): 11111-11123.
58. Xin X, Ferraro F, Back N, et al. Cdk5 and Trio modulate endocrine cell exocytosis. *J Cell Sci*. 2004; 117(20): 4739-4748.
59. de Ligt J, Willemsen MH, van Bon BWM, et al. Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability. *New Engl J Med*. 2012; 367(20): 1921-1929.
60. Vulto-van Silfhout AT, Hehir-Kwa JY, van Bon BWM, et al. Clinical Significance of De Novo and Inherited Copy-Number Variation. *Hum Mutat*. 2013; 34(12): 1679-1687.
61. Pengelly RJ, Greville-Heygate S, Schmidt S, et al. Mutations specific to the Rac-GEF domain of TRIO cause intellectual disability and microcephaly. *J Med Genet*. 2016; 53(11): 735-742.
62. Mercer CL, Keeton B, Dennis NR. Familial multiple ventricular extrasystoles, short stature, craniofacial abnormalities and digital hypoplasia: a further case of Stoll syndrome? *Clin Dysmorphol*. 2008; 17(2): 91-93.
63. Sadybekov A, Tian C, Arnesano C, et al. An autism spectrum disorder-related de novo mutation hotspot discovered in the GEF1 domain of Trio. *Nat Commun*. 2017; 8(1): 601.
64. Katrancha SM, Wu Y, Zhu M, et al. Neurodevelopmental disease-associated de novo mutations and rare sequence variants affect TRIO GDP/GTP exchange factor activity. *Hum Mol Genet*. 2017; 26(23): 4728-4740.
65. Blangy A, Bouquier N, Gauthier-Rouviere C, et al. Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay. *Biol Cell*. 2006; 98(9): 511-522.
66. Charrasse S, Comunale F, Fortier M, et al. MCadherin Activates Rac1 GTPase through the Rho-GEF Trio during Myoblast Fusion. *Mol Biol Cell*. 2007; 18(5): 1734-1743.
67. Kashef J, Kohler A, Kuriyama S, et al. Cadherin-11 regulates protrusive activity in *Xenopus* cranial neural crest cells upstream of Trio and the small GTPases. *Genes Dev*. 2009; 23(12): 1393-1398.
68. Li Y, Guo Z, Chen H, et al. HOXC8-Dependent Cadherin 11 Expression Facilitates Breast Cancer Cell Migration through Trio and Rac. *Genes Cancer*. 2011; 2(9): 880-888.
69. Timmerman I, Heemskerk N, Kroon J, et al. A local VE-cadherin and Trio-based signaling complex stabilizes endothelial junctions through Rac1. *J Cell Sci*. 2015; 128(16): 3041-3054.
70. van Rijssel J, Kroon J, Hoogenboezem M, et al. The Rho-GEF Trio controls leukocyte transendothelial migration by promoting docking structure formation. *Mol Biol Cell*. 2012.
71. Wei Q, Adelstein RS. Pitx2a Expression Alters Actin-Myosin Cytoskeleton and Migration of HeLa Cells through Rho GTPase Signaling. *Mol Biol Cell*. 2002; 13(2): 683-697.
72. Salhia B, Tran NL, Chan A, et al. The Guanine Nucleotide Exchange Factors Trio, Ect2, and Vav3 Mediate the Invasive Behavior of Glioblastoma. *Am J Pathol*. 2008; 173(6): 1828-1838.
73. Fortin SP, Ennis MJ, Schumacher CA, et al. Cdc42 and the Guanine Nucleotide Exchange Factors Ect2 and Trio Mediate Fn14-Induced Migration and Invasion of Glioblastoma Cells. *Molecular cancer research MCR*. 2012; 10(7): 958-968.
74. van Rijssel J, Hoogenboezem M, Wester L, et al. The N-terminal DH-PH domain of Trio induces cell spreading and migration by regulating lamellipodia dynamics in a Rac1-dependent fashion. *PLoS One*. 2012; 7(1): e29912.
75. Cannet A, Schmidt S, Delaval B, et al. Identification of a mitotic Rac-GEF, Trio, that counteracts MgcRacGAP function during cytokinesis. *Mol Biol Cell*. 2014; 25(25): 4063-4071.

76. Vaque JP, Dorsam RT, Feng X, et al. A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors. *Mol Cell*. 2013; 49(1): 94-108.
77. Valdivia A, Goicoechea SM, Awadia S, et al. Regulation of circular dorsal ruffles, macropinocytosis, and cell migration by RhoG and its exchange factor. *Trio Mol Biol Cell*. 2017; 28(13): 1768-1781.
78. Plageman Jr TF, Chauhan BK, Yang C, et al. A Trio-RhoA-Shroom3 pathway is required for apical constriction and epithelial invagination. *Development*. 2011; 138): 5177-5188.
79. Lee JW, Yeo SG, Kang BH, et al. Echovirus 30 Induced Neuronal Cell Death through TRIO-RhoA Signaling Activation. *PLoS One*. 2012; 7(5): e36656.